Adam J. Gordon
banner
adamjgordon.bsky.social
Adam J. Gordon
@adamjgordon.bsky.social
Adam J. Gordon MD MPH FACP DFASAM. Husband-Father-Scholar-Teacher-Professor-Physician-Friend-Editor-HaikuMaker-MasterGardener. Internal Medicine Addiction Medicine. Professor of Medicine & Psychiatry. Director #PARCKA #VIP #SCOUTT. Editor #SAj Views=my own
Reposted by Adam J. Gordon
Appreciate co-authors @adamjgordon.bsky.social and others for their collaboration and @FOREfdn for supporting this research
December 2, 2024 at 2:46 PM
Reposted by Adam J. Gordon
4/ Addressing systemic barriers and stigma and supporting clinicians who prescribe buprenorphine for opioid use disorder is crucial for improving treatment access. Read the full paper here: journals.sagepub.com/doi/abs/10.1...
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
December 19, 2024 at 8:49 PM
Reposted by Adam J. Gordon
3/ Even in counties with high opioid overdose rates, the removal of the X-waiver didn't significantly impact buprenorphine access.
December 19, 2024 at 8:49 PM
Reposted by Adam J. Gordon
2/ We explored if removing the X-waiver improved treatment access by examining whether buprenorphine prescriptions increased in counties with higher OD rates and fewer waivered prescribers compared to others. We found no significant effect of the X-waiver elimination on buprenorphine dispensation
December 19, 2024 at 8:49 PM